5ed0377f-26aa-4b4c-bb59-03001895aecd
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.700
- INTERFERON_GAMMA_RESPONSE+0.600
- ALLOGRAFT_REJECTION+0.500
- IL6_JAK_STAT3_SIGNALING+0.400
- OXIDATIVE_PHOSPHORYLATION+0.400
- ADIPOGENESIS+0.300
- APICAL_SURFACE+0.300
- COMPLEMENT+0.300
- FATTY_ACID_METABOLISM+0.300
- HEME_METABOLISM+0.300
Top 10 suppressed
- NOTCH_SIGNALING-0.400
- ANGIOGENESIS-0.300
- E2F_TARGETS-0.300
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.300
- G2M_CHECKPOINT-0.300
- MYC_TARGETS_V1-0.300
- UV_RESPONSE_DN-0.200
- APICAL_JUNCTION-0.100
- COAGULATION-0.100
- DNA_REPAIR-0.100
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | fea785bb-de96-4411-8bf4-a7d254af9ff9 | — | — | 0.888 |
| 2 | SRR8518426 | — | C | 0.808 |
| 3 | TCGA-A8-A09Z-01A-11R-A00Z-07 | — | B | 0.802 |
| 4 | ERR2208892 | — | — | 0.798 |
| 5 | BS_AG3D3435 | subependymal giant cell astrocytoma(SEGA) | — | 0.792 |
| 6 | ERR2208921 | — | — | 0.789 |
| 7 | TCGA-E2-A1IK-01A-11R-A144-07 | — | B | 0.784 |
| 8 | d3be84d5-9dd7-4366-9aea-532dc76f19ba | — | — | 0.781 |
| 9 | BS_3TQSE8HF | subependymal giant cell astrocytoma(SEGA) | — | 0.772 |
| 10 | MNG1165 | — | — | 0.772 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 31 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.700 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.600 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.500 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.400 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.400 | Remibrutinib | — uncovered |
| ADIPOGENESIS | 0.300 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.300 | Temsirolimus | — uncovered |
| COMPLEMENT | 0.300 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.300 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.300 | Temsirolimus | — uncovered |
| INFLAMMATORY_RESPONSE | 0.300 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.300 | Cobimetinib | — uncovered |
| PEROXISOME | 0.300 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.300 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.200 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.200 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.200 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.200 | Inavolisib | — uncovered |
| HYPOXIA | 0.200 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.200 | Idelalisib | — uncovered |